Equities Analysts Set Expectations for USNA FY2025 Earnings

USANA Health Sciences, Inc. (NYSE:USNA) – Analysts at Sidoti Csr boosted their FY2025 earnings per share (EPS) estimates for USANA Health Sciences in a report issued on Thursday, January 15th. Sidoti Csr analyst A. Lebiedzinski now anticipates that the company will post earnings of $1.74 per share for the year, up from their previous forecast of $1.73. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share. Sidoti Csr also issued estimates for USANA Health Sciences’ Q4 2025 earnings at $0.41 EPS, Q1 2027 earnings at $0.65 EPS, Q2 2027 earnings at $0.67 EPS, Q3 2027 earnings at $0.74 EPS and FY2027 earnings at $2.81 EPS.

A number of other research firms have also recently weighed in on USNA. Weiss Ratings reaffirmed a “sell (d)” rating on shares of USANA Health Sciences in a report on Monday, December 29th. Zacks Research cut USANA Health Sciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, January 7th. Finally, Wall Street Zen lowered USANA Health Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Two research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average price target of $36.00.

USANA Health Sciences Trading Up 5.5%

NYSE:USNA opened at $21.60 on Friday. The firm has a market capitalization of $394.87 million, a PE ratio of 24.55, a price-to-earnings-growth ratio of 0.90 and a beta of 0.65. The stock has a 50 day moving average of $19.79 and a 200-day moving average of $25.37. USANA Health Sciences has a 52 week low of $18.48 and a 52 week high of $38.32.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Wednesday, October 22nd. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.47 by ($0.62). USANA Health Sciences had a return on equity of 6.97% and a net margin of 1.86%.The firm had revenue of $213.67 million during the quarter, compared to analyst estimates of $224.97 million. USANA Health Sciences has set its FY 2025 guidance at 1.730-1.730 EPS.

Institutional Trading of USANA Health Sciences

Several institutional investors have recently modified their holdings of the company. Envestnet Portfolio Solutions Inc. bought a new stake in shares of USANA Health Sciences during the 2nd quarter worth $274,000. Pzena Investment Management LLC lifted its holdings in USANA Health Sciences by 9.4% during the 2nd quarter. Pzena Investment Management LLC now owns 1,198,260 shares of the company’s stock worth $36,583,000 after buying an additional 103,074 shares during the period. Allianz Asset Management GmbH acquired a new stake in shares of USANA Health Sciences during the second quarter worth $638,000. KLP Kapitalforvaltning AS increased its holdings in USANA Health Sciences by 82.6% in the second quarter. KLP Kapitalforvaltning AS now owns 19,900 shares of the company’s stock worth $608,000 after purchasing an additional 9,000 shares in the last quarter. Finally, Public Employees Retirement System of Ohio grew its holdings in USANA Health Sciences by 51.0% in the second quarter. Public Employees Retirement System of Ohio now owns 23,520 shares of the company’s stock worth $718,000 after purchasing an additional 7,943 shares during the period. Institutional investors and hedge funds own 54.25% of the company’s stock.

Insider Activity at USANA Health Sciences

In other USANA Health Sciences news, Director Frederic J. Winssinger sold 2,000 shares of the company’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $19.21, for a total transaction of $38,420.00. Following the completion of the sale, the director directly owned 5,986 shares in the company, valued at $114,991.06. This represents a 25.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John Turman Fleming sold 1,750 shares of the firm’s stock in a transaction dated Friday, October 31st. The shares were sold at an average price of $19.79, for a total value of $34,632.50. Following the completion of the sale, the director directly owned 4,565 shares in the company, valued at approximately $90,341.35. This represents a 27.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 5,680 shares of company stock worth $114,090. Corporate insiders own 0.63% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.